Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer

NOBUHITO KUBOTA1, FUMITAKA TANIGUCHI1, AKIHIRO NYUYA2, YUZO UMEDA1, YOSHIKO MORI1, TOSHIYOSHI FUJIIWARA1, HIROAKI TANIOKA2, ATSUHI TSURUTA3, YOSHIYUKI YAMAGUCHI2 and TAKESHI NAGASAKA2

1Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558; Departments of 2Clinical Oncology and 3Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama 701-0192, Japan

Received July 8, 2019; Accepted November 14, 2019

DOI: 10.3892/ol.2020.11365

Abstract. Colorectal cancer (CRC) manifests after the accumulation of genetic and epigenetic alterations along with tumor microenvironments. MicroRNA (miRNA/miR) molecules have been revealed to serve in critical roles in the progression various types of cancer, and their expression level is often an important diagnostic, predictive or prognostic biomarker. The aim of the present study was to evaluate the potential of miRNAs as prognostic biomarkers for patients with advanced CRC. miRNA arrays were performed on CRC specimens obtained from tumors with various molecular statuses [e.g. KRAS proto-oncogene, GTPase (KRAS)/B-Raf proto-oncogene, serine/threonine kinase (BRAF)/microsatellite instability (MSI)], and their paired normal mucosal specimens. The miRNA array revealed that miR-31-5p (miR-31) was specifically upregulated in CRCs with the BRAF V600E mutation, the results of which were supported by subsequent analysis of a dataset retrieved from The Cancer Genome Atlas (TCGA) database, which contained information regarding 170 patients with CRC including 51 BRAF-mutant CRCs. Of our cohort of 67 patients with stage IV CRC, 15 (22%) and 4 (6%) showed KRAS and BRAF V600E mutations, respectively. Since the median miR-31 expression was 3.45 (range, 0.004-6330.531), the cut-off value was chosen as 3.5, and all tumors were categorized into two groups accordingly (high-/low-miR-31 expression). The high miR-31 expression group (n=33) was significantly associated with a poorer mortality (univariate hazard ratio=2.12; 95% confidence interval, 0.23-0.95; P= 0.03) and exhibited a shorter median survival time (MST; 20.1 months) compared with the low miR-31 expression group (n=34) (MST, 38.3 months; P=0.03), indicating that miR-31 is a promising prognostic biomarker for patients with advanced CRC. Thus, performing a functional analysis of miR-31 expression may lead to the development of new targeted therapies for the various genetic subtypes of CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer type and is a leading cause of cancer-associated mortality worldwide (1,2). A certain subset of CRC arises from the sequential accumulation of genetic and epigenetic alterations. microRNAs (miRNA/miR) have been revealed as candidates in tumor progression in various cancer types, and changes in their expression levels are consequently being investigated with the purpose of identifying clinical biomarkers (3-9). miRNAs constitute a class of small, non-coding RNA molecules, 18-27 nucleotides in length that function as post-transcriptional regulators of gene expression, either serving as oncogenes or tumor suppressor genes (10,11). In CRC, several miRNAs are aberrantly expressed and target genes downstream of epidermal growth factor receptor (EGFR) signaling; for example, miR-143 and -145 target KRAS and BRAF proteins, respectively (12). Nosho et al (13) revealed that high miR-31-5p (miR-31) expression [miR-31 has the two subtypes; miR-31 (hsa-mir-31-5p) and miR-31* (hsa-mir-31-3p)] was significantly associated with BRAF V600E mutation (P<0.0001) and a poorer prognosis in a large statistical population of 721 patients with CRC. Additionally, downregulation of BRAF protein expression, following transfection of an miR-31 inhibitor into CRC cells was demonstrated (13). Thus, the aforementioned evidence indicates that miR-31 may regulate the activation of BRAF...
protein in CRC, and may also serve an important role in the downstream EGFR signaling pathway.

The present study investigated miR-31 that is significantly associated with advanced CRC with BRAF V600E mutation, as the presence of BRAF mutations is known to be a poor prognostic factor in CRC (14-18). According to the results of the microarray analysis, it was revealed that miR-31 expression is upregulated in BRAF-mutant tumors. Therefore, the association between miR-31 expression levels and BRAF-mutant CRCs was further investigated using a dataset retrieved from The Cancer Genome Atlas (TCGA) database. Finally, miR-31 expression patterns observed in CRC were further supported by investigating the miR-31 expression level in patients with stage IV CRC.

Materials and methods

Patients. From a cohort of 598 patients with CRC, 129 patients with stage IV CRC underwent primary tumor resection before other treatments, such as chemotherapy, radiotherapy or chemoradiotherapy, at Okayama University Hospital (Okayama, Japan) between March 2003 and May 2013. Of these, only 67 patients were evaluated and analyzed in the present study due to availability of both tumors and the paired normal mucosa (Fig. 1). The tumors and the corresponding normal mucosa were stored at -80˚C following preservation before other treatments, such as chemotherapy, radiotherapy or chemoradiotherapy, at Okayama University Hospital (Okayama, Japan) between March 2003 and May 2013. Of these, only 67 patients were evaluated and analyzed in the present study due to availability of both tumors and the paired normal mucosa (Fig. 1).

DNA and RNA extraction. DNA was extracted from 67 fresh-frozen paired tumor and healthy colonic mucosal tissue specimens, which were obtained from a site adjacent to the primary tumor, >10 cm from the tumor border. DNA from the fresh-frozen tissue specimens was extracted using a QIAamp DNA Mini kit (Qiagen, Inc.) according to the manufacturer's protocol. Total miRNA was isolated from frozen tissue specimens using a miRNeasy Mini kit (Qiagen, Inc.) and analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.) according to the manufacturer's protocol. SurePrint G3 Human miRNA 8x60K Rel.16.0 (Agilent Technologies, Inc.) was used to analyze miRNA expression in paired primary tumor and normal colonic tissue samples. The expression level of each probe was calculated as the sum of 20 spots of raw intensity with the background subtracted. Target miRNAs that were not detected in any spots were defined as ‘undetected’ and allocated an expression level of ‘0.1’. The data were normalized to the 90th percentile, and target miRNAs that were not detected in all the samples were excluded.

BRAF and KRAS mutation analyses. A BRAF mutation in codon 600 and KRAS mutations in codons 12 and 13 were analyzed by direct sequencing using purified DNA from fresh-frozen tissues of each patient. The specific primer sequences and PCR conditions have been described previously (20). The PCR products were purified using a QIAquick PCR purification kit (Qiagen, Inc.) according to the manufacturer's protocol and were directly sequenced on an ABI 310R Genetic Analyzer (Thermo Fisher Scientific, Inc.).

Microsatellite instability (MSI) analysis. A multiplex PCR method for the detection of tumors with MSI was performed to determine the MSI status of all CRC tissues using four mononucleotide repeat markers (BAT26, NR21, NR27 and CAT25) as described previously (21,22). Tumors exhibiting MSI in ≥1 mononucleotide repeat marker were classified as MSI phenotype, whereas those without MSI were classified as non-MSI phenotype.

Analysis of miRNA expression in paired primary tumor and normal colonic tissue samples using miRNA microarray. Total miRNA was isolated from frozen tissue specimens using a miRNeasy Mini kit (Qiagen, Inc.) and analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.) according to the manufacturer's protocol. SurePrint G3 Human miRNA 8x60K Rel.16.0 (Agilent Technologies, Inc.) was used to analyze miRNA expression in paired primary tumor and normal colonic tissue samples. The expression level of each probe was calculated as the sum of 20 spots of raw intensity with the background subtracted. Target miRNAs that were not detected in any spots were defined as ‘undetected’ and allocated an expression level of ‘0.1’. The data were normalized to the 90th percentile, and target miRNAs that were not detected in all the samples were excluded.

Preliminary analysis of the association between miR-31 expression and BRAF mutation using TCGA database. Freely available datasets regarding miRNA expression and somatic mutations of colon adenocarcinoma samples were retrieved from TCGA (23). From TCGA database (v1.0), a total of 187 CRC samples had data available regarding miR-31 expression, among which the BRAF mutation profile was available in 170 CRCs on the GDC Data Portal (https://portal.gdc.cancer.gov/). Thus, miR-31 expression in 170 CRC tissues was subsequently analyzed. Of these, 51 CRCs were categorized as having BRAF V600E mutation (30%).

Reverse transcription-quantitative (RT-q)PCR. Total miRNA was isolated from frozen tissue specimens using a miRNeasy Mini kit (Qiagen, Inc.). The expression levels of miR-31 (Hs_miR-31_1 miScript Primer Assay; Qiagen, Inc.) and RNU6B (Hs_RNU6-2_1 miScript Primer Assay; Qiagen, Inc.) were analyzed using miScript primer assays. The cDNA was generated by a miScript II RT Kit (Qiagen, Inc.). RT-qPCR was performed with the gene-specific primers and a miScript SYBR® Green PCR kit (Qiagen, Inc.) using a LightCycler 480 (Roche Diagnostics), according to the manufacturer's protocol. Briefly, reactions were incubated in a 96-well plate at 95˚C for 15 min, followed by 40 cycles of 95˚C for 15 sec, 55˚C for 30 sec and 70˚C for 30 sec, according to the manufacturer's protocol. The quantitative value of miRNA in a given sample was calculated by subtracting that value from the Cq value of RNU6B, which served as the internal reference gene. Cq values from duplicate reactions were averaged, and the threshold cycle value (∆Cq) was calculated by subtracting the Cq of the RNU6B from the Cq of the target miR-31. The ∆∆Cq value of tumor was calculated by subtracting the ∆Cq value of the normal counterpart sample (24). The value of 2^-ΔΔCq represents the expression relative quotient (RQ) of miR-31. Here, the miR-31 expression level (RQ of miR-31) was presented as the ratio of the miR-31 expression in cancerous tissue vs. adjacent non-cancerous tissue. A miR-31 expression level <1 indicated that the expression levels in cancerous tissue were
lower compared with that in the paired normal colonic tissue. Conversely, an miR-31 expression level >1 indicated higher expression in cancerous tissue compared with that in the paired normal colonic tissue.

Statistical analysis. Statistical analyses were performed using JMP Pro software (version 14.2; SAS Institute Inc.). The miRNA expression level is presented as the mean RQ, and was measured three times in all samples. Categorical variables were compared using a $\chi^2$ test. miR-31 expression levels in BRAF-mutant CRC tissues from TCGA were compared with those in BRAF-wild type CRC tissues using Dunnett’s Method. Disease-specific overall survival time (OS) was calculated from the date of initial treatment to the date of death due to primary colon cancer or last follow-up for censored patients (the patients were followed up every month for stage IV cases). Survival data, <120 months, following initial treatment was used. Survival-based outcomes were analyzed by the Kaplan-Meier method, expressed as medians and compared with log-rank test. Univariate and multivariate analyses were performed using the Cox-proportional hazards model. The hazard ratio (HR) and 95% confidence interval (CI) were calculated from the model, and the significance of the parameters was evaluated using Wald’s test. All reported P-values were from two-sided tests, and P<0.05 was considered to indicate a statistically significant difference.

Results

Identification of miRNAs associated with CRCs expressing the BRAF V600E mutation. Prior to analyzing the miRNA microarray data, six independent CRC specimens were evaluated according to their KRAS/BRAF mutational profiles and MSI status, which resulted in six subtypes with different genetic and clinical features (25). No MSI tumors were observed to exhibit a KRAS-mutation. Therefore, the following specimens were collected: An MSI with BRAF V600E mutation, two non-MSI tumors without either KRAS or BRAF mutation (wild-type), a non-MSI tumor with BRAF V600E mutation, and two non-MSI tumor with KRAS mutation, each located in the right or left side of the colon. The two normal colonic (right colon and rectum) mucosa specimens were used as controls (Fig. 2A and Table S1). The miRNA array provided the expression status of a total of 1,368 miRNAs.

To identify miRNAs that were significantly associated with non-MSI tumors containing the BRAF V600E mutation, miRNAs exhibiting no expression among the six CRC tissues and the two corresponding normal colorectal mucosae (803 miRNAs), and miRNAs that were expressed in all the tissues (286 miRNAs), were excluded. The cluster analysis revealed that only miR-31 was significantly upregulated in non‑MSI CRC specimens with the BRAF V600E mutation (sample ID, 341), while miR-429, -375, -200a, -200b and -192 were downregulated compared with that in the other CRC phenotypes, such as CRCs with wild-type BRAF. Generally, molecules that are significantly and specifically upregulated in tumors are useful for screening those tumors via liquid biopsy or other screening tools (26). Therefore, subsequent analyses focused on miR-31 as a candidate prognostic biomarker in the present study.

Association between miR-31 expression and BRAF-mutant CRC in TCGA database. To confirm whether elevated miR-31 expression is common in BRAF-mutant CRC, miRNA expression and somatic mutations data from colon adenocarcinoma samples retrieved from TCGA were analyzed (Fig. 2B). From the database, a cohort of 170 patients with CRC were available for analysis of miR-31 expression with respect to BRAF mutation status. Among the 170 CRCs, the value of miR-31 expression ranged from 0 to 447.6 (median, 6.27). BRAF mutation was observed in 51 patients with CRC (30%), and all 51 showed higher miR-31 expression (median value, 45.47; 95% CI, 20.59-70.35) compared to patients with CRC expressing wild-type BRAF (median value, 21.57; 95% CI, 13.09-30.05; P=0.0228).

Calculation of miR-31 expression in stage IV CRC specimens. To examine at what point during CRC progression do miR-31
Table I. Clinicopathological features of 67 patients with stage IV CRC stratified by miR-31 expression level.

| Variables                              | Total, n (%) (n=67) | miR-31 expression level, n (%) | P-value |
|----------------------------------------|---------------------|--------------------------------|---------|
|                                        |                     | Low (<3.5) (n=34)             |         |
|                                        |                     | High (≥3.5) (n=33)            |         |
|                                        |                     | P-value                       |         |
| Age, years                             | 64.1 (35-85)        | 62.9 (41-85)                  | 65.3 (35-82) | 0.218 |
| Mean (range)                           |                     | 0.621                         |         |
| <65                                    | 28 (41.8)           | 17 (50.0)                     | 11 (33.3) | 0.218 |
| ≥65                                    | 39 (58.2)           | 17 (50.0)                     | 22 (66.7) | 0.218 |
| Gender                                 | 0.621               |                               |         |
| Female                                 | 26 (38.8)           | 12 (35.3)                     | 14 (42.4) | 0.218 |
| Male                                   | 41 (61.2)           | 22 (64.7)                     | 19 (57.6) | 0.218 |
| Serum CEA level, ng/µl                 | 0.262               |                               |         |
| <5.0                                   | 17 (25.4)           | 11 (32.4)                     | 6 (18.2)  | 0.218 |
| ≥5.0                                   | 50 (74.6)           | 23 (67.6)                     | 27 (81.8) | 0.218 |
| Tumor location                         | 0.392               |                               |         |
| Right                                  | 15 (22.4)           | 6 (17.6)                      | 9 (27.3)  | 0.392 |
| Left                                   | 52 (77.6)           | 28 (82.4)                     | 24 (72.7) | 0.392 |
| Histology                              | 0.186               |                               |         |
| Well or moderate                       | 57 (85.1)           | 31 (91.2)                     | 26 (78.8) | 0.186 |
| Poor or mucinous                      | 10 (14.9)           | 3 (8.8)                       | 7 (21.2)  | 0.186 |
| No. of distant metastatic sites        | 0.194               |                               |         |
| Single                                 | 46 (68.7)           | 26 (76.5)                     | 20 (60.6) | 0.194 |
| Multiple                               | 21 (31.3)           | 8 (23.5)                      | 13 (39.4) | 0.194 |
| T factor                               | 0.2                 |                               |         |
| 1                                      | 1 (1.5)             | 0 (0.0)                       | 1 (3.0)  | 0.2 |
| 2                                      | 4 (6.0)             | 3 (8.8)                       | 1 (3.0)  | 0.2 |
| 3                                      | 38 (56.7)           | 22 (64.7)                     | 16 (48.5) | 0.2 |
| 4a                                     | 15 (22.4)           | 7 (20.6)                      | 8 (24.2)  | 0.2 |
| 4b                                     | 9 (13.4)            | 2 (5.9)                       | 7 (21.2)  | 0.2 |
| N factor                               | 0.437               |                               |         |
| 0                                      | 13 (19.4)           | 9 (26.5)                      | 4 (13.3)  | 0.437 |
| 1a                                     | 11 (16.4)           | 5 (14.7)                      | 6 (18.2)  | 0.437 |
| 1b                                     | 14 (20.9)           | 6 (17.6)                      | 8 (24.2)  | 0.437 |
| 1c                                     | 1 (1.5)             | 1 (2.9)                       | 0 (0.0)  | 0.437 |
| 2a                                     | 13 (19.4)           | 4 (11.8)                      | 9 (27.3)  | 0.437 |
| 2b                                     | 12 (17.9)           | 7 (20.6)                      | 5 (15.2)  | 0.437 |
| X                                      | 3 (4.5)             | 2 (5.9)                       | 1 (3.0)  | 0.437 |
| M factor                               | 0.447               |                               |         |
| 1a                                     | 44 (65.7)           | 24 (54.5)                     | 20 (45.5) | 0.447 |
| 1b                                     | 23 (34.3)           | 10 (43.5)                     | 13 (56.5) | 0.447 |
| MSI status                             | Not calculated      |                               |         |
| MSI                                    | 0 (0.0)             | 0 (0.0)                       | 0 (0.0)  | 0.0608 |
| Non-MSI                                | 67 (100.0)          | 34 (100)                      | 33 (100) | 0.0608 |
| KRAS/RAF mutation status               | 0.0608              |                               |         |
| KRAS mutation                          | 15 (22.4)           | 10 (29.4)                     | 5 (15.2)  | 0.0608 |
| BRAF mutation                          | 4 (6.0)             | 0 (0.0)                       | 4 (12.1)  | 0.0608 |
| Wild-type                              | 48 (71.6)           | 24 (70.6)                     | 24 (72.7) | 0.0608 |

P-values were calculated using χ² test. miR, microRNA; KRAS, KRAS proto-oncogene, GTPase; BRAF, B-Raf proto-oncogene, serine/threonine kinase; MSI, microsatellite instability. T, N and M factor denotes the depth of invasion, the regional lymph node metastasis and the presence or otherwise of distant metastasis defined by the AJCC cancer staging (19). X denotes unclassified of N factor.
expression levels affect clinical outcomes in advanced CRC, a cohort of 67 patients with stage IV CRCs (out of a total of 598), had both frozen tumor and adjacent normal mucosa tissues available for RNA extraction, were selected (Fig. 1). Of the 67 stage IV CRC specimens, all of them were non-MSI. The median \( \text{miR-31} \) expression level was 3.45 (mean, 142; range, 0.004-6330.531). Therefore, a cut-off value of 3.5 was used. Cases showing an \( \text{miR-31} \) expression level ≥3.5 were included in the \( \text{miR-31} \) high-expression group, while cases with an \( \text{miR-31} \) expression level <3.5 were categorized as low expression. According to this classification, 33 and 34 cases were defined as \( \text{miR-31} \) high expression and \( \text{miR-31} \) low expression, respectively. Table I displays the clinicopathological features of patients with stage IV CRCs as classified by \( \text{miR-31} \) expression level. Of the 67 stage IV CRCs, only four had a \( \text{BRAF} \) mutation and were all included in the \( \text{miR-31} \) high-expression group; however, the association was not significant. Additionally, there were no significant differences in clinicopathological characteristics between the two groups.

Clinical outcomes are associated with \( \text{miR-31} \) expression status in patients with stage IV CRCs. Among the cohort of 67 patients with stage IV CRCs, the median survival time (MST) was 29 months (95% CI, 19.5-38 months; Fig. 3A). Stratification of patients according to their \( \text{BRAF/KRAS} \) mutation status was then conducted; the MST of patients with \( \text{BRAF} \)-mutant, \( \text{KRAS} \)-mutant and wild-type CRC was 1.8, 29 and 30 months, respectively (Fig. 3B; \( P<0.0001 \)). Next, clinical outcomes were analyzed with respect to \( \text{miR-31} \) expression status. The MST of the \( \text{miR-31} \) high expression group was 20 months, while that of the \( \text{miR-31} \) low expression group was 38 months (Fig. 4A; \( P=0.0314 \)). Of note, the four patients with \( \text{BRAF} \)-mutant CRCs (MST, 1.8 months) were all in the \( \text{miR-31} \) high-expression group, and the prognosis of the \( \text{miR-31} \) high-expression group may have been affected by this subgroup of patients. Therefore, during subsequent prognostic analysis patients with \( \text{BRAF} \)-mutant CRC were excluded. The \( \text{miR-31} \) high expression group still maintained a tendency toward poor prognosis compared with the \( \text{miR-31} \) low-expression group, although it did not reach statistical significance (Fig. 4B).

Finally, univariate and multivariate analyses were conducted using the Cox-proportional hazards model to determine the factors that influenced poorer outcomes in patients with stage IV CRC (Table II). The univariate analysis revealed that tumors with poor or mucinous histology, multiple distant metastatic sites, the \( \text{BRAF} \text{V600E} \) mutation and higher \( \text{miR-31} \) expression levels statistically exhibited a poorer prognosis; however, in the multivariate analysis, only multiple distant metastatic sites and the presence of the \( \text{BRAF} \text{V600E} \) mutation, indicated a poorer prognosis.

Discussion

In the present study, the potential of \( \text{miR-31} \) as a prognostic biomarker for patients with advanced CRC was demonstrated, particularly in patients with stage IV of the disease. \( \text{miR-31} \) is
miR-31 is located on chromosome 9p21.3 and is reportedly deregulated in various types of human cancer, for example, esophageal, breast, ovarian and gastric cancers (3,27-30). Moreover, in CRC, an association has been reported between upregulation of miR-31 and poor tumor differentiation (13), oncogenic potential (13,31-34), deeper invasion (34,35) and advanced disease stages (31,34,35).

In the advanced stages of CRC, the presence of BRAF mutations is demonstrated to be a poor prognostic factor (14-18), so specific miRNAs that are significantly associated with BRAF...
mutations were investigated in the present study. The results obtained from a miRNA array analysis revealed that miR-31 was upregulated in BRAF-mutant CRC tissues compared with that in other CRC subtypes, such as KRAS-mutant or wild-type CRCs. The association between miR-31 and BRAF mutations was also confirmed in a dataset comprising information on 170 patients with CRC, retrieved from TCGA database.

In addition to its association with the BRAF oncogene, miR-31 has been demonstrated to bind to the 3' untranslated region of special AT-rich sequence-binding protein 2 (SATB2), which is a nuclear matrix-associated transcription factor and epigenetic regulator, downregulating its expression at both the mRNA and protein level (36). SATB2 was originally identified as a highly tissue-specific protein, predominantly expressed in glandular cells of the lower gastrointestinal tract, and high expression of SATB2 is an accurate prognostic marker in CRC (37,38).

Another target of miR-31 is RAS p21 GTPase-activating protein 1 (RASA1), which is a negative regulator of the RAS-RAF-MEK-ERK signal pathway (39). Overexpression of miR-31 downregulates RASA1 protein but not RASA1 mRNA, suggesting that miR-31 regulates RASA1 expression via a post-transcriptional mechanism. RASA1, with its C-terminal GAP domain, has the ability to stimulate the GTPase activity of normal RAS p21, which results in the inactivation of RAS. Thus, overexpression of miR-31 in CRC may repress RASA1 and consequently upregulate the RAS pathway to promote tumor cell proliferation. Furthermore, miR-31 promotes epithelial-mesenchymal transition (EMT) (34,40). Cottonham et al (34) reported that CRC cell lines with elevated miR-31 expression undergo EMT (a factor associated with distant metastasis) in response to transforming growth factor (TGF)-β, without influencing the TGF-β pathway. Meng et al (41) reported that miR-31 was upregulated in lung adenocarcinoma tissues from patients with lymph node metastases, compared with those without. Additionally, in vitro functional assays demonstrated that miR-31 increased cell migration, invasiveness and proliferation in an ERK1/2 signaling-dependent manner (40).

Thus, upregulation of miR-31 may enhance tumor development, as well as the malignant potential of a tumor, via inhibition of SATAB2 and RASA1, enhancement of EMT and upregulation of BRAF expression. Particularly, miR-31 upregulation is commonly observed in BRAF-mutant CRCs, which may enhance the downstream proteins of RAS-RAF signal cascade.

Regarding molecular targeting therapies, there are several reports indicating the influence of the expression status of miR-31 (either -3p alone or both -3p and -5p) on the sensitivity of metastatic CRC (with wild-type RAS) to anti-EGFR therapy (42-44). Patients with higher miR-31 expression levels exhibited poorer outcomes during treatment with anti-EGFR therapy. As miR-31 upregulates BRAF protein levels irrespective of the RAS/BRAF mutation status and inhibits RASA1 mRNA (which inactivates activated RAS by stimulating GTPase) (13,39), it is hypothesized that upregulation of miR-31 inhibits the efficacy of anti-EGFR therapy, and acts in a manner similar to oncogenic mutations in the RAS and RAF genes.

To the best of our knowledge, the most effective treatment strategy for patients with stage IV CRC and BRAF mutations, which may be associated with high miR-31 expression levels (13), is currently unknown. The answer may exist in a recent clinical trial for unresectable patients with BRAF V600E mutant CRC, called the BEACON study (45). BRAF inhibition has been revealed to improve clinical outcomes in patients with melanoma and non-small cell lung cancer that have a BRAF V600 mutation; however, in patients with CRC, BRAF inhibition has only conferred a marginal improvement in the reduction of tumor burden (46-53). Notably, in vitro studies demonstrated that in BRAF V600E-mutant CRC cells, BRAF inhibition results in the rapid feedback activation of EGFR, permitting sustained MAPK activation and continued cell proliferation; however, combined inhibition of BRAF and EGFR resulted in synergistic inhibition of tumor growth in BRAF V600E mutant CRC xenograft models (54,55). Subsequent clinical studies of EGFR-targeted therapies, combined with the BRAF inhibitors vemurafenib or dabrafenib, confirmed that addition of an EGFR-targeted therapy may improve the activity of BRAF inhibition in BRAF V600E-mutant CRC (55-57). In the BEACON study (45), patients
with CRC and the BRAF V600E mutation, who had experienced treatment failure with one or two prior chemotherapy regimens, were recruited and treated with three molecular target agents, encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor) and cetuximab (an EGFR inhibitor). In 29 patients with BRAF V600E mutant tumors, the overall response rate was 48%, the median progression-free survival was 8.0 months and the median OS time was 15.3 months (45). This indicates that the BRAF V600E mutation serves as a facilitator of CRC progression and therapies are required that inhibit the feedback activation of RAS-RAF signal cascade.

The present study demonstrated that high miR-31 expression was associated with BRAF V600E mutation in patients with stage IV CRC, but also indicated a poor prognosis, irrespective of BRAF mutation status. Additionally, an inhibitor to miR-31 may confer a clinical benefit on patients with CRC with BRAF V600E mutation or high miR-31 expression levels, perhaps as part of a combination therapy alongside BRAF inhibitors, MEK inhibitors and EGFR inhibitors.

In the present study, despite the small population size, analysis of miRNA microarray data and relevant samples from TCGA database showed the reproducible result that high miR-31 expression was associated with a BRAF mutation and poor outcome in CRC, as demonstrated by a previous study (13). The results from the current strongly indicate that the expression level of miR-31 in the primary cancer site is a promising prognostic factor for CRC regardless of the RAS/BRAF mutation profile as well as a predictive factor for anti-EGFR treatment in CRCs with wild-type RAS/BRAF. Thus, miR-31 may represent a favorable biomarker and a promising therapeutic target in patients with CRC.

Acknowledgements

The authors would like to thank Mr. Toru Nakai and Mrs. Tae Yamanishi (Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) and Mrs. Kikue Tokuda (Clinical Oncology, Kawasaki Medical School, Okayama, Japan) for their technical assistance.

Funding

The present study was supported by The Ministry of Education, Culture, Sports, Science and Technology (MEXT)/Japan Society of the Promotion of Science (JSPS) KAKENHI (grant nos. 20590572, 25860409, 26462016, 18H03554 and 18K18464).

Availability of data and materials

The datasets generated and analyzed during the present study are available in the National Cancer Institute repository (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga).

Authors’ contributions

NK performed miRNA analysis and drafted the manuscript. FT performed TCGA data analysis. AN, YM and HT performed all DNA extractions and KRAS/BRAF mutation and MSI analyses. YU collected patient samples, clinicopathological data, assisted with data interpretation and performed statistical analyses. TF provided patient samples, clinicopathological data and designed the study. AT and YY assisted with data interpretation and revised the manuscript. TN assisted with data interpretation, designed the project, secured the funding and drafted the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by The Ethics Committee of Okayama University Hospital and Kawasaki Medical School Hospital. All patients provided written informed consent.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
3. Yu T, Ma P, Wu D, Shu Y and Gao W: Functions and mechanisms of microRNA-31 in human cancers. Biomed Pharmacother 108: 1162-1169, 2018.
4. Kopcalic K, Petrovic N, Stanojkovic TP, Stankovic V, Bukumiric Z, Roganovic J, Malisic E and Nikitovic M: Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. Pathol Res Pract 215: 626-631, 2019.
5. Braga TV, Evangelista FCG, Gomes LC, Araujo SSS, Carvalho MDG and Sabino AP: Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia. Biomed Pharmacother 92: 864-869, 2017.
6. Petrovic N: miR-21 might be involved in breast cancer promotion and invasion rather than in initial events of breast cancer development. Mol Diagn Ther 20: 97-110, 2016.
7. Tofiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 105: 849-859, 2013.
8. Hur K, Tofiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A: MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62: 1315-1326, 2013.
9. Fuji T, Umeda Y, Nyuya A, Taniguchi F, Kawai T, Yasui K, Yoshima T, Yoshida K, Fujiwara T, Goel A and Nagasaka T: Detection of circulating microRNAs with Ageo2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. Int J Cancer 144: 2169-2180, 2019.
10. Lee RC and Ambros V: An extensive class of small RNAs in caenorhabditis elegans. Science 294: 862-864, 2001.
11. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
12. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R and Ricci-Vitiani L: Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32: 4806-4813, 2013.
13. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, Naito T, Sakawa Y, Mikami M, Sumioka W, et al: Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 35: 776-783, 2014.
14. Samowitz WS, Sweeney J, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK and Slattery ML: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colorectal cancers. J Clin Oncol 35: 6507-6514, 2017.

15. Mori Y, Nakagasa T, Hama R, Nishizaki M, Hayaga J, Furuta S, Nakamura K, Fujiwara T, Boland CR and Goel A: BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 15: 2195-2201, 2018.

16. Mori Y, Nakagasa T, Umeda Y, Mishima H, Goel A and Fujiwara T: BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 15: 2195-2201, 2018.

17. Mori Y, Nakagasa T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Nagasaka T, Hamelin R and Boland CR: An optimized workflow for microRNA-31-5p/3p as a predictive biomarker of colorectal cancer progression by repressing its target gene SATB2. PLoS One 8: e55353, 2013.

18. Nagasaka T, Mori Y, Umeda Y and Fujiwara T: BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 15: 2195-2201, 2018.

19. Nagasaka T, Mori Y, Umeda Y, Mishima H, Goel A and Fujiwara T: BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 15: 2195-2201, 2018.

20. Nagasaka T, Mori Y, Umeda Y and Fujiwara T: BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 15: 2195-2201, 2018.

21. Goel A, Nakagasa T, Hamelin R and Boland CR: An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5: e9393, 2010.

22. Nakagasa T, Mori Y, Umeda Y and Fujiwara T: BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer. Oncol Lett 15: 2195-2201, 2018.
52. Planchnard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, et al: Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. Lancet Oncol 17: 984-993, 2016.

53. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373: 726-736, 2015.

54. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2: 227-235, 2012.

55. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, et al: Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6: 1352-1365, 2016.

56. Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, et al: Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8: 428-443, 2018.

57. Connolly K, Brungs D, Szeto E and Epstein RJ: Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. Curr Oncol 21: e151-e154, 2014.